Lembas
Develops bioactive peptides to stimulate GLP-1 production for food and supplement companies.
Website: https://www.hellolembas.com/
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Name | Lembas |
| Tagline | Develops bioactive peptides to stimulate GLP-1 production for food and supplement companies. [AgFunderNews, June 2025] |
| Headquarters | Israel |
| Founded | 2024 |
| Stage | Pre-seed [AgFunderNews, June 2025] |
| Business model | B2B [Crunchbase] |
| Industry | Deeptech |
| Technology | Biotech / Life Sciences |
| Geography | Middle East / North Africa |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (3+) [United with Israel] |
| Funding label | Pre-seed |
| Total disclosed | $3.6 million [AgFunderNews, June 2025] |
Links
Publicly reported
- LinkedIn: https://www.linkedin.com/in/shayhilel/
Summary and Signal
PUBLIC Lembas is an Israeli biotech ingredient startup building bioactive peptides for food and supplement companies, and it merits investor attention because it is positioning itself at the intersection of GLP-1 demand, functional ingredients, and AI-assisted discovery just as the category is drawing fresh capital and strategic interest [AgFunderNews, June 2025] [GlobeNewswire, October 2026] [bakeryandsnacks.com, September 2026]. The company emerged from stealth in June 2025 with a $3.6 million pre-seed round led by FLORA Ventures, framing its founding around a non-drug approach to appetite and metabolic support through everyday food formats rather than injectable therapeutics [AgFunderNews, June 2025] [Forbes, June 2025].
Its lead product, GLP-1 Edge, is described as a patent-pending peptide ingredient intended to stimulate production of GLP-1 and related gut hormones, with proposed use across supplements, bars, shakes, snacks, and beverages; the differentiating claim is not merely formulation, but a licensed Tel Aviv University technology stack that uses AI to discover, design, and screen food-grade bioactive peptides [AgFunderNews, June 2025] [Crunchbase] [Green Queen]. Those claims remain early and mostly company-sourced, although multiple outlets consistently describe the same product concept and licensing origin [AgFunderNews, June 2025] [Forbes, June 2025] [Substack].
The founding bench is more technical than commercial in the public record. Shay Hilel is identified as CEO and co-founder, Dr. Zohar Barbash as CTO and co-founder, Prof. Maayan Gal as CSO and co-founder, and Dr. Daniel Bar as a co-founder; public profiles also point to prior startup work by Hilel and Barbash, and scientific credentials around molecular biology and research leadership on the technical side [AgFunderNews, June 2025] [LinkedIn] [Crunchbase].
The business model appears straightforward B2B ingredient sales, with peptide powder supplied to food and supplement brands rather than direct-to-consumer distribution, which fits the capital-efficient logic of selling into existing channels if efficacy, regulatory positioning, and manufacturing scale hold up [Crunchbase] [Forbes, June 2025]. For investors, the next 12 to 18 months likely turn on three public milestones: whether Lembas can move from preclinical-style signaling into human validation, whether it can convert category interest into named commercial relationships, and whether it can defend a credible moat around peptide discovery and IP in a fast-forming GLP-1 companion foods market projected to grow from $3.60 billion in 2026 to $16.58 billion by 2036 [AgFunderNews, June 2025] [GlobeNewswire, October 2026].
One source, partially checked -- Summary relies on one independently reported financing event and multiple corroborating but partly company-derived descriptions of product, team, and technology [AgFunderNews, June 2025] [Forbes, June 2025] [Crunchbase].
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | Middle East / North Africa |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Pre-seed, total disclosed approximately $3.6 million [AgFunderNews, June 2025] |
Company Overview
PUBLIC
Lembas appears to be a young Israeli biotech ingredient startup built around a narrow, commercially legible thesis: food-grade peptides that may influence metabolic signaling, sold business-to-business rather than as a consumer brand [Crunchbase]. Crunchbase lists the company as founded in 2024 and describes its offering as a peptide powder ingredient for food and supplement brands, which is enough to place the company in the ingredients layer of the value chain even if public detail on the legal entity remains thin [Crunchbase].
The public chronology is short but coherent. The company was founded in 2024, then emerged from stealth in June 2025 alongside disclosure of a $3.6 million pre-seed round led by FLORA Ventures, according to AgFunderNews [AgFunderNews, June 2025]. In the same coverage, Lembas presented its initial product as "GLP-1 Edge," a patent-pending bioactive peptide, and said the underlying technology was licensed from Tel Aviv University [AgFunderNews, June 2025].
On location and leadership, the public record supports Israel as headquarters and a founding group of at least four executives and scientists, with Shay Hilel identified publicly as CEO and co-founder, Zohar Barbash as CTO and co-founder, Prof. Maayan Gal as CSO and co-founder, and Dr. Daniel Bar as co-founder across LinkedIn and other public profiles [LinkedIn, retrieved 2026] [United with Israel, retrieved 2026]. The more conservative read is that the company has cleared the first visibility milestone, financing plus public launch, while most operating details that matter for later-stage diligence, such as entity structure, customer adoption, and regulatory pathway, are not yet established in the cited company-level sources [Crunchbase] [AgFunderNews, June 2025].
One source, partially checked -- Founded date and B2B company description are supported by Crunchbase, while the June 2025 launch and financing details are supported by AgFunderNews; legal entity details were not confirmed in the cited company-level sources.
The Product and the Stack
MIXED
Lembas is positioning itself as an ingredient company rather than a consumer brand, and the distinction matters because the product claim sits at the intersection of food formulation and metabolic health. Public coverage describes its lead offering, GLP-1 Edge, as a patent-pending bioactive peptide ingredient sold business-to-business for use in supplements and packaged food formats such as bars, shakes, snacks, and beverages [AgFunderNews, June 2025] [Crunchbase] [Forbes, June 2025]. The company says the ingredient is designed to stimulate production of GLP-1 and other gut hormones involved in appetite and metabolism, with the more conservative public framing being that it is intended to enhance the body’s own GLP-1 response rather than replace GLP-1 drugs [AgFunderNews, June 2025] [Edible Planet Ventures] [Healthtech Alpha].
The underlying technology story is still early, but it is at least directionally consistent across multiple public references. AgFunderNews reported that Lembas licenses its technology from Tel Aviv University and uses artificial intelligence to discover, design, and screen bioactive peptides [AgFunderNews, June 2025]. Other public references describe the same core stack as a patent-pending computational discovery platform for food-grade peptides, although the operational evidence remains pre-commercial and mostly company-derived [Green Queen] [Substack] [PR Newswire]. The strongest technical signal in the available record is not human efficacy data, which has not been established in the cited material, but reported preclinical progress: Green Queen says Lembas scientists observed positive cell and animal model results with GLP-1 secretion into the blood [Green Queen]. For investors, that leaves the product in a familiar deeptech posture, credible scientific framing, clear formulation pathways, and a still-unproven bridge from preclinical signal to repeatable commercial ingredient performance.
No independent source found -- Core product and mechanism claims are largely company-derived or reported by single publications, with partial corroboration from Crunchbase and other secondary public references.
The Market They Are Entering
PUBLIC
The market matters now because GLP-1 drugs have moved from a pharmaceutical story into a food formulation problem, and that shift is beginning to create a distinct ingredient opportunity set for companies that can fit inside consumer packaged goods workflows [FoodNavigator, October 2025] [FoodNavigator, October 2026].
Third-party market sizing is still narrow, but there is at least one named report framing the category around "GLP-1 companion foods." GlobeNewswire cited that market at $2.90 billion in 2025, $3.60 billion in 2026, and $16.58 billion by 2036, implying a 16.5% CAGR over 2026 to 2036 [GlobeNewswire, October 2026]. That is not a direct read-through to Lembas, which sells a business-to-business ingredient rather than finished consumer products, but it is the closest public proxy in the record for the commercial space Lembas appears to be targeting through food and supplement brands [Crunchbase] [AgFunderNews, June 2025].
GLP-1 companion foods 2025 | 2.9 | $B
GLP-1 companion foods 2026 | 3.6 | $B
GLP-1 companion foods 2036 | 16.58 | $B
The chart points to a category that is still small relative to mainstream packaged food, but expanding fast enough to attract new ingredient suppliers if the end products hold shelf space and repeat purchase [GlobeNewswire, October 2026]. For Lembas, the implication is less about absolute market size today and more about whether brands increasingly want functional inputs tied to appetite, satiety, protein balance, and metabolic health positioning [FoodNavigator, October 2025] [FoodNavigator, October 2026].
Demand drivers look clearer than the competitive map. FoodNavigator reported in 2025 and 2026 that food and beverage groups were actively adapting products around the eating patterns of GLP-1 users, with emphasis on protein density, nutrient adequacy, portion size, and products designed to support weight management routines [FoodNavigator, October 2025] [FoodNavigator, October 2026]. In parallel, Lembas is positioning its peptide as an input for supplements, bars, shakes, snacks, and beverages, which aligns with formats that can be reformulated faster than conventional center-store staples [AgFunderNews, June 2025].
Capital is also starting to follow the theme, even if the evidence here is broader than Lembas's exact niche. bakeryandsnacks.com reported that private equity investment in packaged-food and meat producers reached $5.92 billion in the first seven months of 2026, against a backdrop of GLP-1-driven changes in food valuations and product planning [bakeryandsnacks.com, September 2026]. That does not prove sustained demand for bioactive peptide ingredients, but it does suggest investors and strategics are treating GLP-1-linked food behavior as commercially relevant rather than speculative [bakeryandsnacks.com, September 2026].
The more realistic frame is that Lembas sits between several adjacent markets rather than inside one fully formed category. The nearest public analog is GLP-1 companion foods, but substitute and neighboring budgets likely sit in sports nutrition, weight-management supplements, metabolic health ingredients, and functional foods that target satiety or blood sugar support rather than GLP-1 specifically [GlobeNewswire, October 2026] [FoodNavigator, October 2025]. That matters because adoption may come from brands reallocating existing formulation spend, not from an entirely new category line item.
Regulatory and macro conditions remain a gating factor. The cited market reports make clear that telehealth expansion and wider GLP-1 drug use are helping shape demand for specialized food products [GlobeNewswire, October 2026]. But Lembas's commercial path still depends on how food and supplement claims can be substantiated and positioned in each market, especially if the product is presented as supporting appetite regulation or metabolic health rather than functioning as a drug substitute, a distinction reflected in public descriptions of GLP-1 Edge [Forbes, June 2025] [Edible Planet Ventures].
One source, partially checked -- Section uses one named third-party sizing report, two sector publications on GLP-1 food demand, and company positioning references from AgFunderNews and Crunchbase; the category proxy is directionally relevant but not a direct measure of Lembas's addressable ingredient market.
The Competitive Field
MIXED
Lembas is not competing in a clean startup-defined lane so much as at the intersection of food ingredients, metabolic health, and the fast-forming market around GLP-1-adjacent nutrition, which means its real alternatives span branded food incumbents, supplement formulators, and obesity drugs themselves [AgFunderNews, June 2025] [FoodNavigator, October 2025] [FoodNavigator, October 2026].
The clearest way to map the field is by segment rather than by startup peer set, because no named early-stage direct competitors were confirmed in the source set. On one side sit large food and beverage companies building products for GLP-1 users, a trend FoodNavigator described as a broader "GLP-1 food and beverage boom," with major brands moving into higher-protein, satiety-oriented, and portion-aware formats [FoodNavigator, October 2025] [FoodNavigator, October 2026]. On another side sit supplement and ingredient companies that can formulate appetite, metabolic, or gut-health claims into powders, bars, and beverages, the same product surfaces Lembas is targeting with GLP-1 Edge [AgFunderNews, June 2025] [Forbes, June 2025]. The adjacent substitute is more consequential still: prescription GLP-1 drugs, which are already reshaping food innovation and M&A behavior, according to FoodNavigator and bakeryandsnacks.com [FoodNavigator, October 2026] [bakeryandsnacks.com, September 2026].
Where Lembas appears differentiated today is in the form factor and discovery stack it is presenting to brand customers. Public reporting describes GLP-1 Edge as a patent-pending bioactive peptide ingredient sold B2B, with applications across supplements, bars, shakes, snacks, and beverages, and ties that ingredient to technology licensed from Tel Aviv University [AgFunderNews, June 2025] [Crunchbase] [Forbes, June 2025]. That creates a potentially useful positioning wedge: rather than launching a consumer food brand into a crowded shelf set, Lembas is trying to become an enabling ingredient supplier inside other companies' products [Crunchbase] [AgFunderNews, June 2025]. The edge is credible but still perishable. A university-licensed, patent-pending platform and a biology-plus-AI discovery workflow may matter if they produce repeatable peptide hits and defensible IP, but public evidence at this stage is still mostly company-sourced product characterization rather than independently validated commercial or clinical advantage [AgFunderNews, June 2025] [Green Queen] [Substack].
The company is most exposed where incumbents already own the customer relationship or the proof standard. Large food groups can move quickly if GLP-1-oriented nutrition becomes a durable category, and they already control shelf access, formulation teams, and marketing budgets, as reflected in sector reporting on major brands entering the space [FoodNavigator, October 2025] [FoodNavigator, October 2026]. At the same time, drug makers and the clinical weight-loss ecosystem set the reference point for efficacy. Lembas does not need to replace drugs, and one source explicitly says it is not positioning itself as a drug replacement, but any ingredient framed around endogenous GLP-1 stimulation will still be judged against a much higher efficacy bar than ordinary functional foods face [Edible Planet Ventures] [Forbes, June 2025]. That leaves the company in a narrow middle ground: more science-heavy than a standard wellness ingredient, but without the regulatory moat or outcome data usually associated with therapeutics in the public record provided here [AgFunderNews, June 2025].
The most plausible 18-month scenario is that the category fragments into two visible winners, one in consumer distribution and one in enabling ingredients. Nestle looks like the likely winner if mass-market GLP-1 companion nutrition is defined by branded meals and established channels, because incumbents can absorb trend shifts faster once demand is legible, a pattern already visible in broader GLP-1 food coverage and related reporting on companion products [FoodNavigator, October 2025] [FoodNavigator, October 2026] [Forbes, May 2024]. Lembas is the more interesting winner if food and supplement brands decide they want a differentiated ingredient input rather than only a marketing label, and if its peptide platform can convert early scientific promise into formulation wins and human data [AgFunderNews, June 2025]. The more likely loser if consumer enthusiasm runs ahead of measurable product performance is the undifferentiated supplement layer broadly, since those products would be easiest for buyers to swap out if efficacy claims tighten or the category consolidates around better-capitalized branded foods and clinically adjacent offerings [FoodNavigator, October 2025] [FoodNavigator, October 2026].
One source, partially checked -- Competitive framing is grounded in FoodNavigator, AgFunderNews, Forbes, and bakeryandsnacks.com, but no named direct startup competitors were confirmed in the source set and several Lembas differentiation claims remain company-linked or single-source.
Opportunity
Upside case
PUBLIC The prize here is not a niche ingredient line, but a position inside a new food-and-supplement stack forming around GLP-1-era eating behavior, a market that one industry report sizes at $3.60 billion in 2026 and $16.58 billion by 2036 [GlobeNewswire, October 2026].
The headline opportunity is straightforward. If Lembas can show that its peptide ingredient works reliably, safely, and in forms consumer brands can actually ship, it has a path to become a key enabling supplier for GLP-1 companion foods rather than a single finished-product brand fighting for shelf space [AgFunderNews, June 2025] [Crunchbase] [GlobeNewswire, October 2026]. That outcome is reachable, not merely aspirational, because the company is already positioned as a business-to-business ingredient vendor, its first product is framed for use across supplements, bars, shakes, snacks, and beverages, and the underlying technology is reported as licensed from Tel Aviv University rather than built as a one-off formulation experiment [AgFunderNews, June 2025] [Crunchbase] [Substack].
The category context matters. Food and beverage incumbents are already responding to GLP-1-driven demand shifts, with FoodNavigator documenting both a broader GLP-1 food and beverage boom and how weight-loss drugs are reshaping product innovation across the sector [FoodNavigator, October 2025] [FoodNavigator, October 2026]. Against that backdrop, an ingredient company that helps brands formulate for satiety, appetite regulation, or metabolic-health positioning could slot into many SKUs and many channels at once, which is a larger outcome than building one consumer label from scratch [AgFunderNews, June 2025] [Forbes, June 2025].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Multi-brand ingredient standard | Lembas becomes a repeat supplier of GLP-1-oriented peptide ingredients to food and supplement brands across several product formats | A successful first commercial launch in one or more of the formats already cited for GLP-1 Edge, such as bars, shakes, or beverages [AgFunderNews, June 2025] | The product is already described as a B2B peptide powder for food and supplement companies, and the addressable category is forecast to expand materially over the next decade [Crunchbase] [GlobeNewswire, October 2026] |
| Discovery platform plus pipeline | GLP-1 Edge becomes the first of several food-grade bioactive ingredients discovered through the same AI-led peptide screening approach | Validation that the discovery engine can generate additional compounds beyond the first appetite and metabolism use case [AgFunderNews, June 2025] [Green Queen] | Multiple sources describe the company as using AI to discover, design, analyze, and screen food-grade bioactive peptides, which suggests platform ambition rather than a single-asset story [AgFunderNews, June 2025] [Green Queen] [Substack] |
| Strategic acquisition target | A large ingredient, nutrition, or food company buys Lembas to secure a differentiated GLP-1 companion-food capability early | Category tipping point as incumbents accelerate M&A and product investment around GLP-1-related consumption changes [bakeryandsnacks.com, September 2026] [FoodNavigator, October 2026] | Sector capital is already moving. bakeryandsnacks.com reported $5.92 billion of private equity investment into packaged-food and meat producers in the first seven months of 2026, while trade coverage shows major food companies adapting product roadmaps to GLP-1 demand shifts [bakeryandsnacks.com, September 2026] [FoodNavigator, October 2026] |
What compounding looks like is less about a classic consumer network effect and more about ingredient-platform economics. One commercial win can do three things at once: create formulation proof for adjacent brands, produce more biological and application data for the peptide discovery engine, and deepen switching costs if a brand formulates the ingredient into products across several categories [AgFunderNews, June 2025] [Crunchbase] [Green Queen]. The early signs are still narrow and mostly company-linked, but they point in the right direction: Lembas is not presenting GLP-1 Edge as a single finished product, it is presenting it as a food-grade input that can travel across multiple product formats, and the company describes a broader AI system for peptide discovery rather than a static ingredient catalog [AgFunderNews, June 2025] [Substack].
That matters because compounding in ingredients can be quiet but powerful. If one peptide can move from supplements into bars, shakes, snacks, and beverages, then each validation event should reduce commercial friction for the next formulation cycle [AgFunderNews, June 2025]. If the AI-led discovery stack is real and repeatable, the business could also accumulate a library of food-grade bioactives that expands its negotiating position with brands over time, especially in a market that GlobeNewswire projects will grow from $3.60 billion in 2026 to $16.58 billion by 2036 [GlobeNewswire, October 2026].
The size of the win is easiest to frame through category value rather than an unsupported venture multiple. If Lembas were to become a meaningful enabling supplier in the companion-food layer of the GLP-1 ecosystem, even a low-single-digit share of the projected 2036 market would be substantial. On GlobeNewswire's $16.58 billion 2036 market estimate, a 1% share implies roughly $165.8 million in annual market capture (scenario, not a forecast), while a 3% share implies about $497.4 million (estimated) (scenario, not a forecast) [GlobeNewswire, October 2026]. Those figures are not revenue forecasts for Lembas, and they assume the market definition is directionally useful, but they do show why investors are paying attention to enabling infrastructure around GLP-1 behavior shifts rather than only to the drug makers themselves.
One source, partially checked -- Relies on one independently cited market-sizing source, one independently cited funding report, and several company-linked or single-source product claims from AgFunderNews, Crunchbase, Green Queen, Forbes, and Substack.
Sources
Publicly reported
[AgFunderNews, June 2025] Pharma is eating Big Food’s lunch. Lembas fights back with GLP-1-boosting peptide | https://agfundernews.com/pharma-is-eating-big-foods-lunch-lembas-fights-back-with-glp-1-boosting-peptide
[GlobeNewswire, October 2026] Global GLP-1 Companion Foods Market Size, Share, Trends, and Forecast 2026-2036 | Industry to Reach US$16.58 Billion as Protein-Rich Innovation and Telehealth Expansion Drive 16.5% CAGR | https://www.globenewswire.com/news-release/2026/10/28/3390453/28124/en/global-glp-1-companion-foods-market-size-share-trends-and-forecast-2026-2036-industry-to-reach-us-16-58-billion-as-protein-rich-innovation-and-telehealth-expansion-drive-16-5-cagr.html
[bakeryandsnacks.com, September 2026] How GLP-1 drugs are reshaping food M&A valuations | https://www.bakeryandsnacks.com/Article/2026/09/23/how-glp-1-drugs-are-reshaping-food-ma-valuations
[Forbes, June 2025] Lembas GLP-1 Ingredient Manufacturer Enters The Market Following $3.6 Million Pre-Seed Investment | https://www.forbes.com/sites/andrewwatman/2025/06/10/lembas-glp-1-ingredient-manufacturer-enters-the-market-following-36-million-pre-seed-investment/
[Crunchbase, retrieved 2026] Lembas | https://www.crunchbase.com/organization/lembas
[Green Queen, retrieved 2026] Lembas startup profile | https://www.greenqueen.com.hk/
[LinkedIn, retrieved 2026] Shay Hilel - Lembas | LinkedIn | https://www.linkedin.com/in/shayhilel/
[FoodNavigator, October 2025] GLP-1 food and beverage boom: Market growth, big brands, and key challenges | https://www.foodnavigator.com/Article/2025/10/15/glp-1-food-and-beverage-boom-market-growth-big-brands-and-key-challenges
[FoodNavigator, October 2026] How GLP-1 weight-loss drugs are reshaping food and beverage innovation | https://www.foodnavigator.com/Article/2026/10/08/how-glp-1-weight-loss-drugs-are-reshaping-food-and-beverage-innovation
[HackSummit, retrieved 2026] Where Europe's Climate Hard Tech Comes Together | HackSummit 2026 | https://www.hacksummit.co/
[United with Israel, retrieved 2026] Lembas company profile | https://unitedwithisrael.org/
[Edible Planet Ventures, retrieved 2026] Lembas portfolio profile | https://www.edibleplanetventures.com/
[Healthtech Alpha, retrieved 2026] Lembas company profile | https://www.healthtechalpha.com/
[Substack, retrieved 2026] Lembas company profile | https://substack.com/
[PR Newswire, retrieved 2026] Lembas announcement | https://www.prnewswire.com/
[Forbes, May 2024] Weight Loss Drug Boom Won't Eat Into Food Industry Profits, Nestlé CEO Says | https://www.forbes.com/sites/roberthart/2024/05/30/weight-loss-drugs-wont-eat-into-food-industry-profits-nestl-ceo-says/
Articles about Lembas
- A Tel Aviv University License Underpins Lembas's GLP-1 Ingredient Bet — The Israeli startup's B2B ingredient, designed to stimulate gut hormones, enters a market projected to reach $16.6 billion by 2036.